医学
四肽
免疫疗法
肺癌
癌症研究
化疗
非小细胞肺癌
肿瘤科
内科学
癌症
生物化学
A549电池
化学
肽
作者
M.L. Johnson,C.E. Steuer,H. Hayashi,W.-C. Su,M. Nishio,D.-W. Kim,M. Koczywas,E. Felip,K.A. Gold,H. Murakami,C.S. Baik,S.-W. Kim,E.F. Smit,M. Gigantone,B. Kim,P.-D. Fan,Z. Qi,E.Y. Wu,D. Sternberg,P.A. Jänne
标识
DOI:10.1016/j.jtho.2022.09.074
摘要
Patients with advanced NSCLC without EGFR-activating mutations (EGFRm) have limited treatment options after failure of molecularly targeted therapies or platinum-based chemotherapy (PBC) with or without immunotherapy (IO). HER3-DXd is an antibody drug conjugate consisting of a fully human anti-HER3 mAb attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Here we present updated results, previously presented at ASCO 2022, in patients without tumor EGFRm who progressed after PBC ± IO treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI